VEXAS syndrome: 2026 so far

Retrospective data increasingly compared clone clearance across approaches.

In the months covered, multicenter retrospective comparisons and a transplant-focused review looked more directly at whether treatments can eliminate the UBA1-mutated blood-cell clone. In these reports, allogeneic hematopoietic stem cell transplantation (allo-HSCT, a donor stem cell transplant that replaces the blood-forming system) was linked to higher rates of molecular remission (UBA1 becoming undetectable) and to more frequent glucocorticoid (steroid) discontinuation than hypomethylating agents (drugs that change how genes are switched on/off) such as azacitidine. Deaths were reported in both groups during follow-up. The same publications also stressed that transplant can have serious risks, including graft-versus-host disease (GVHD, donor immune cells attacking the body) in some patients, which affects how the potential for UBA1-clone clearance is weighed against complication risk.

Research covered in: June 2026

Cohorts clarified limits of cytokine blockers and steroid-sparing.

Cohort reports in the months covered gave a clearer real-world view of how often commonly used anti-inflammatory drugs lead to lasting control. In a 52-person cohort, IL-6 inhibitors and JAK inhibitors sometimes reduced inflammation, but complete responses were uncommon. Many patients discontinued within 6-12 months, and sustained steroid-sparing was described as limited overall. In that cohort, IL-1 and TNF inhibitors rarely helped (with small numbers treated). Other observational work again noted that steroids often bring rapid improvement but tapering is frequently difficult. Hypomethylating agents (e.g., azacitidine) were described as slower-acting, with some reports of more sustained improvement, including transfusion independence (no longer needing blood transfusions) in case reports, which helps set expectations that many people may need to try more than one therapy and still may not reach lasting, steroid-free control with cytokine blockers alone.

Research covered in: January 2026, May 2026, September 2026

Field moved toward shared decision-making and shared measurement tools.

In the months covered, reports described VEXAS care as more coordinated and more standardized, rather than handled entirely case-by-case. A UK national multidisciplinary team (MDT, a group of specialists making decisions together) report described real-world cross-center discussions. These discussions more often leaned toward steroid-sparing options (including azacitidine and tocilizumab) and included some referrals for transplant evaluation, without proving any option is best. Separately, experts agreed on a new VEXAS disease activity index (VEXAS-DAI, a scoring tool to rate disease activity) across 12 organ systems, meant to standardize how flares and responses are described, though validation was still pending. This mainly changes how consistently decisions and treatment responses can be discussed and compared across centers and studies.

Research covered in: February 2026, July 2026

Registries linked specific features to higher complication and outcome risk.

Registry and cohort studies in the months covered added clearer signals about who may face higher near-term risk, though the studies were observational. Thrombosis (blood clots in veins or arteries) stood out as a prominent complication. An Italian VEXAS cohort reported clots were common (including new clots after diagnosis), and some events occurred despite anticoagulation (blood thinners), often around flares. A separate 40-person cohort supported clotting involvement with blood markers consistent with endothelial activation (blood vessel lining being 'switched on') and increased clotting tendency. Other registry work linked recurrent fever with heavier overall illness (including more organ involvement) and higher mortality in that dataset. A Japanese registry associated higher UBA1 variant allele fraction (the share of blood cells carrying the mutation) and a higher starting prednisolone dose with a higher one-year risk of death or becoming transfusion-dependent. These findings show that serious outcomes like clotting are being measured and tied to specific clinical or lab features, even though predicting risk for an individual person remains uncertain.

Research covered in: March 2026, April 2026, August 2026, September 2026

Reports emphasized targeted suspicion plus quicker genetic confirmation.

In the months covered, diagnostic updates shifted from general reminders toward practical tools meant to shorten time to confirmation. Reports again noted that VEXAS can look like other inflammatory or bone marrow conditions, and that UBA1 testing often becomes the deciding step, supported by blood counts and bone marrow findings such as vacuoles (small empty-looking spaces inside cells). Newer work proposed a five-feature clinical score (older onset, skin lesions, chondritis (inflammation of cartilage), macrocytic anemia (anemia with larger-than-usual red blood cells), bone marrow vacuoles). In one cohort, this score separated likely VEXAS from look-alikes and performed well in external validation sets. Another report described a rapid allele-specific PCR assay (a quick DNA test for specific mutations) that detected common UBA1 codon 41 hotspot mutations in a small prospective group, while not ruling out VEXAS if negative. Where these screening and rapid-testing approaches are used, they may reduce diagnostic detours, while broader sequencing is still needed for non-hotspot variants.

Research covered in: January 2026, May 2026, June 2026, July 2026